These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36068472)

  • 1. The Pharmacogenetic Impact on the Pharmacokinetics of ADHD Medications.
    Brown JT
    Methods Mol Biol; 2022; 2547():427-436. PubMed ID: 36068472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.
    Brown JT; Bishop JR
    Pharmacogenomics; 2015; 16(13):1513-20. PubMed ID: 26314574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial.
    Fijal BA; Guo Y; Li SG; Ahl J; Goto T; Tanaka Y; Nisenbaum LK; Upadhyaya HP
    J Clin Pharmacol; 2015 Oct; 55(10):1167-74. PubMed ID: 25919121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.
    Yu G; Li GF; Markowitz JS
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):314-26. PubMed ID: 26859445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
    Osland ST; Steeves TD; Pringsheim T
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically Significant Drug-Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder.
    Schoretsanitis G; de Leon J; Eap CB; Kane JM; Paulzen M
    CNS Drugs; 2019 Dec; 33(12):1201-1222. PubMed ID: 31776871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy.
    Brown JT; Bishop JR; Sangkuhl K; Nurmi EL; Mueller DJ; Dinh JC; Gaedigk A; Klein TE; Caudle KE; McCracken JT; de Leon J; Leeder JS
    Clin Pharmacol Ther; 2019 Jul; 106(1):94-102. PubMed ID: 30801677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate.
    Nijenhuis M; Soree B; Jama WOM; de Boer-Veger NJ; Buunk AM; Guchelaar HJ; Houwink EJF; Rongen GA; van Schaik RHN; Swen JJ; Touw D; van der Weide J; van Westrhenen R; Deneer VHM; Risselada A
    Eur J Hum Genet; 2023 Dec; 31(12):1364-1370. PubMed ID: 36509836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A precision medication study of atomoxetine in children with attention deficit hyperactivity disorder:
    Fu D; Guo HL; Hu YH; Chen F
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Jan; 25(1):98-103. PubMed ID: 36655671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE; Kratochvil CJ
    Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
    Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
    Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simple pharmacokinetic models accounting for drug monitoring results of atomoxetine and its 4-hydroxylated metabolites in Japanese pediatric patients genotyped for cytochrome P450 2D6.
    Notsu Y; Shimizu M; Sasaki T; Nakano A; Ota M; Yoshida S; Yamazaki H
    Drug Metab Pharmacokinet; 2020 Apr; 35(2):191-200. PubMed ID: 32184039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD.
    Brown JT; Abdel-Rahman SM; van Haandel L; Gaedigk A; Lin YS; Leeder JS
    Clin Pharmacol Ther; 2016 Jun; 99(6):642-50. PubMed ID: 26660002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.
    Michelson D; Read HA; Ruff DD; Witcher J; Zhang S; McCracken J
    J Am Acad Child Adolesc Psychiatry; 2007 Feb; 46(2):242-51. PubMed ID: 17242628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD.
    Nemoda Z; Angyal N; Tarnok Z; Gadoros J; Sasvari-Szekely M
    Neuropharmacology; 2009 Dec; 57(7-8):731-3. PubMed ID: 19733552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential interactions of methylphenidate and atomoxetine with dextromethorphan.
    Ciccone PE; Ramabadran K; Jessen LM
    J Am Pharm Assoc (2003); 2006; 46(4):472-8. PubMed ID: 16913391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Translating Pharmacogenetics to Clinical Practice: Do Cytochrome P450 2D6 Ultrarapid Metabolizers Need Higher Atomoxetine Doses?
    de Leon J
    J Am Acad Child Adolesc Psychiatry; 2015 Jul; 54(7):532-4. PubMed ID: 26088654
    [No Abstract]   [Full Text] [Related]  

  • 19. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial.
    Ni HC; Hwang Gu SL; Lin HY; Lin YJ; Yang LK; Huang HC; Gau SS
    J Psychopharmacol; 2016 May; 30(5):459-67. PubMed ID: 26905919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.